Kura Oncology Grants Stock Options to New Employees

SAN DIEGO, Sept. 04, 2026 /CourierPR/ -- Kura Oncology, a biopharmaceutical company dedicated to precision medicines for cancer treatment, has announced the granting of inducement awards to new employees. On September 1, 2026, the Compensation Committee of Kura’s Board of Directors granted nonstatutory stock options to purchase 48,450 shares of common stock to four new hires, in line with Nasdaq Listing Rule 5635(c)(4).

The inducement awards were designed to bolster the new employees’ employment, with each option having an exercise price of $12.89 per share, equivalent to the closing price of Kura’s common stock on the grant date. These options will vest over a four-year period, with 25% of the underlying shares vesting on the one-year anniversary of the grant date. The remaining shares will vest monthly over the next 36 months, contingent on the new employees' continued service with the company.

Kura Oncology, headquartered in San Diego, focuses on developing small molecule drug candidates targeting cancer signaling pathways, particularly for high-need hematologic malignancies and solid tumors. The company’s portfolio includes KOMZIFTI® (ziftomenib), an FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Kura is also at the forefront of advancements in menin inhibition and farnesyl transferase inhibition.

The inducement awards reflect Kura’s commitment to attracting and retaining top talent as it continues to advance its pipeline of innovative cancer treatments.